Thromboembolic Risk Stratification by TRiP(Cast) Score to Guide Physicians in Preventive Treatment Prescriptions for Patients With Lower Limb Trauma Requiring Brace or castING.

NCT04064489 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2123

Last updated 2022-08-11

No results posted yet for this study

Summary

Non-surgical traumas to the lower limbs that require orthopedic immobilisation (plaster or splint) are a frequent reason for going to accident and emergency. Due to venous stasis caused by immobilisation, hypercoagulable states and vascular injuries brought on by the trauma, these patients are at risk of developing VTE. For this reason, it is current practice in France and Belgium for the majority of patients to receive a preventative anticoagulant treatment. However, the benefit of this treatment, which has a considerable cost, is controversial. Contrary to French recommendations, American recommendations from 2012 actually advise against systematic preventative medicine, with prevention appearing to be effective primarily in studies with restrictive inclusion criteria. The most significant randomised controlled study on the subject did not show the benefit of low-molecular-weight heparin (LMWH) on the rate of symptomatic VTE among 1,435 non-selected patients. Therefore, in 2017, the Cochrane meta-analysis concluded that stratification of the risk of thromboembolism is required.

For this purpose, in collaboration with the Dutch team of Nemeth et al. we have recently developed a risk stratification model that takes into consideration the patient's characteristics, the type of immobilisation and the severity of the trauma: the TRiP(cast) score. This score is applied retrospectively to a large cohort and demonstrates excellent prognostic performances (AUC (area under the curve) of 0.74). In addition, when using a \<7 limits, it makes it possible to identify a large group of patients at very low risk of developing VTE (negative predictive value: 99.2%).

The aim of the CASTING study is to prospectively demonstrate the reliability and utility of the TRiP(cast) score by showing that patients with orthopaedic immobilisation of a lower limb who are not receiving preventative treatment on the basis of a TRiP(cast) score of \<7 have a very low rate of symptomatic VTE, which allows for a significant reduction in prescriptions of anticoagulants in comparison with prior practices.

Conditions

  • Lower Limb Trauma
  • Venous Thromboembolism
  • Stratification

Interventions

OTHER

TRIPscore

TRIPcast score calculation

Sponsors & Collaborators

  • Centre Hospitalier de Cholet

    collaborator OTHER
  • Centre Hospitalier de Saint-Brieuc

    collaborator OTHER
  • Bichat Hospital

    collaborator OTHER
  • Hôpital Cochin

    collaborator OTHER
  • University Hospital, Toulouse

    collaborator OTHER
  • University Hospital, Grenoble

    collaborator OTHER
  • Centre Hospitalier Régional d'Orléans

    collaborator OTHER
  • Poitiers University Hospital

    collaborator OTHER
  • Nantes University Hospital

    collaborator OTHER
  • Cliniques universitaires Saint-Luc- Université Catholique de Louvain

    collaborator OTHER
  • University Hospital, Tours

    collaborator OTHER
  • CHU Rennes - Hopital Pontchaillou

    collaborator OTHER
  • Centre Hospitalier le Mans

    collaborator OTHER
  • Centre Hospitalier d'Agen

    collaborator OTHER
  • University Hospital, Angers

    lead OTHER_GOV

Principal Investigators

  • Pierre-Marie Roy, MD PhD · University Hospital, Angers

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-16
Primary Completion
2022-02-04
Completion
2022-02-04

Countries

  • Belgium
  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04064489 on ClinicalTrials.gov